Enfusion, Inc. (NYSE:ENFN) General Counsel Sells $12,409.88 in Stock

Enfusion, Inc. (NYSE:ENFN) General Counsel Matthew Campobasso sold 1,081 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $11.48, for a total transaction of $12,409.88. Following the transaction, the general counsel now owns 72,641 shares in the company, valued at approximately $833,918.68. This trade represents a 1.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Matthew Campobasso also recently made the following trade(s):

• On Wednesday, March 5th, Matthew Campobasso sold 1,695 shares of Enfusion stock. The shares were sold at an average price of $11.38, for a total transaction of $19,289.10.
• On Tuesday, January 7th, Matthew Campobasso sold 976 shares of Enfusion stock. The shares were sold at an average price of $10.13, for a total transaction of $9,886.88.

Enfusion Stock Down 0.5 %

Shares of NYSE ENFN opened at $11.24 on Friday. The business’s 50 day moving average price is $10.98 and its 200 day moving average price is $9.88. The firm has a market cap of $1.44 billion, a P/E ratio of 280.95, a P/E/G ratio of 1.85 and a beta of 0.95. Enfusion, Inc. has a 52 week low of $7.83 and a 52 week high of $11.80.

Enfusion (NYSE:ENFN) last released its quarterly earnings data on Monday, March 3rd. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.02). Enfusion had a return on equity of 6.67% and a net margin of 1.70%. The company had revenue of $52.94 million during the quarter, compared to analysts’ expectations of $53.98 million. As a group, research analysts expect that Enfusion, Inc. will post 0.06 earnings per share for the current year.

Institutional Investors Weigh In On Enfusion

Several hedge funds have recently bought and sold shares of the stock. Mackenzie Financial Corp boosted its position in Enfusion by 4.8% in the 4th quarter. Mackenzie Financial Corp now owns 31,271 shares of the company’s stock worth $322,000 after purchasing an additional 1,434 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Enfusion by 43.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 33,721 shares of the company’s stock worth $347,000 after purchasing an additional 10,173 shares in the last quarter. Squarepoint Ops LLC boosted its position in Enfusion by 136.2% in the 4th quarter. Squarepoint Ops LLC now owns 35,633 shares of the company’s stock worth $367,000 after purchasing an additional 20,550 shares in the last quarter. State of Wyoming boosted its position in Enfusion by 52.7% in the 4th quarter. State of Wyoming now owns 76,814 shares of the company’s stock worth $791,000 after purchasing an additional 26,525 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC purchased a new stake in Enfusion in the 4th quarter worth approximately $4,300,000. Hedge funds and other institutional investors own 81.05% of the company’s stock.

Analysts Set New Price Targets

ENFN has been the topic of several recent analyst reports. Piper Sandler upped their price objective on shares of Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a report on Monday, December 23rd. William Blair reiterated a “market perform” rating on shares of Enfusion in a research report on Monday, January 13th. Finally, Stifel Nicolaus upped their target price on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $11.13.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.